Trinity Biotech plc (TRIB)

Trinity Biotech Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	61.56	56.83	62.52	81.15	101.98
Revenue Growth (YoY)	8.31%	-9.10%	-22.96%	-20.43%	12.77%
Cost of Revenue	40.11	37.38	45.25	47.7	53.4
Gross Profit	21.44	19.45	17.27	33.45	48.58
Selling, General & Admin	28.82	31.15	26.98	22.5	25.07
Research & Development	4.54	4.38	4.14	4.5	5.08
Other Operating Expenses	1.79	-0.14	-0.34	-0	-0.02
Operating Expenses	35.15	35.39	30.78	27	30.13
Operating Income	-13.7	-15.94	-13.51	6.46	18.45
Interest Expense	-11.91	-10.15	-11.53	-7.09	-5.54
Interest & Investment Income	-	1.17	-	0	0.04
Other Non Operating Income (Expenses)	-1.17	-	0.23	1.22	-1.22
EBT Excluding Unusual Items	-26.78	-24.92	-24.81	0.6	11.73
Merger & Restructuring Charges	-4.18	-	-	-	-2.43
Impairment of Goodwill	-1.6	-5.83	-	-3.85	-
Gain (Loss) on Sale of Investments	0.8	-1.5	-	-	-
Asset Writedown	-0.61	-3.77	-5.36	-2.51	-17.22
Other Unusual Items	1.64	-0.91	-13.61	3.84	1.28
Pretax Income	-30.73	-36.93	-43.78	-1.92	-6.63
Income Tax Expense	0.49	-0.06	-0.19	-0.07	-0.62
Earnings From Continuing Operations	-31.22	-36.87	-43.59	-1.85	-6.01
Earnings From Discontinued Operations	-0.57	12.85	2.58	2.73	-0.38
Net Income	-31.79	-24.02	-41.01	0.88	-6.39
Net Income to Common	-31.79	-24.02	-41.01	0.88	-6.39
Shares Outstanding (Basic)	18	8	7	4	4
Shares Outstanding (Diluted)	18	8	7	4	4
Shares Change (YoY)	134.62%	13.46%	61.40%	-	-
EPS (Basic)	-1.77	-3.14	-6.08	0.21	-1.53
EPS (Diluted)	-1.83	-3.14	-6.08	0.21	-1.53
Free Cash Flow	-4.6	-12.36	-2.02	11.43	20.55
Free Cash Flow Per Share	-0.26	-1.61	-0.30	2.73	4.92
Gross Margin	34.83%	34.22%	27.62%	41.23%	47.64%
Operating Margin	-22.26%	-28.05%	-21.61%	7.96%	18.09%
Profit Margin	-51.64%	-42.26%	-65.59%	1.08%	-6.26%
Free Cash Flow Margin	-7.47%	-21.75%	-3.23%	14.08%	20.15%
EBITDA	-13.03	-14.17	-11.22	9.18	21.52
EBITDA Margin	-21.17%	-24.92%	-17.94%	11.31%	21.11%
D&A For EBITDA	0.68	1.78	2.29	2.72	3.08
EBIT	-13.7	-15.94	-13.51	6.46	18.45
EBIT Margin	-22.26%	-28.05%	-21.61%	7.96%	18.09%

Updated Dec 31, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q